Scholars Central

Conference abstractPublished 26 Oct 2015

Developments in analytical methods (QC) to meet US-FDA & EU requirements for rDNA therapeutic proteins (MAB’s) with special emphasis on the companies & their problems from Asia (India)

Authors: Shivraj Dasari

SLS Cell Cure Technologies Private Limited, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The old paradigm of process defines the product is being replaced by analytical methods defining the product. With more and more IND products losing their patents in the coming years, the biosimilar war is only going to hot up more. As more countries put in place a regulatory system to regulate the biosimilars, the requirements for biosimilars for entry into the regulated markets will be very keenly fought by the biosimilar players. The expectations of the regulators namely US, EU and the Asian regulations would be discussed in detail. The expectations of the analytical methods and some of the industrial benchmarks for release benchmarks, etc., will be discussed. Though, the expectations of structural evidence for the active substance (including comparison with reference or natural product), post-translational modifications, conformational data for macromolecules with special reference to recombinant antibodies, immunological characterization, expression of purity, strength, etc., would be discussed in detail.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Shivraj Dasari”